INTEREST
Meeting category
Date(s)
10 May 2022 - 13 May 2022
Program Language
English, French
Location
Kampala, Uganda
Meeting type
Hybrid Meeting
Organiser

INTEREST 2022

Related Enduring Materials

Enduring Materials
Tuesday, 10 May 2022
Session 2: COVID-19 and HIV Intersection - 2nd James Hakim Memorial Lectures -
The Impact of COVID-19 on the HIV Cascade
Adeeba Kamarulzaman, MBBS, FRACP, FAMM, FASc HonLLD Monash, DPMP
President and Pro Vice Chancellor, Monash University, Malaysia
Evolving COVID-19 Variants, Immune Escape, and Implications for Vaccination Program
Salim Abdool Karim, FRS
CAPRISA, South Africa
Oral Abstract Presentations I -
#2 - Increasing TB/COVID-19 Case Detection Through Diagnostics Program Integration
David Segun Adeniyi
Nigeria
#3 - Low-Level of Archived Resistance to Integrase Inhibitors Among Third-Line Patients Under Dolutegravir-Based Regimens in Cameroon: Implications for Future Therapeutics
Ezechiel Ngoufack Jagni Semengue
Cameroon
Session 3: COVID-19, Programmatic, Clinical, and Biological Interactions -
Innovative TB Programming within the Context of COVID-19
Lucica Ditiu, MD
Stop TB Partnership, Switzeland
Biologic Interactions Between COVID-19 and HIV
Penny Moore, PhD
University of the Witwatersrand / National Institute for Communicable Diseases, South Africa
Session 4: Improving Access to COVID-19 and HIV Medicines in Africa -
Accessing COVID 19 Antivirals and New Long Acting Agents in Africa
Tiwadayo Braimoh, MSc, MBA
Medicines Patent Pool, Switzerland
Wednesday, 11 May 2022
Session 6: HIV Prevention -
HIV Prevention Studies and Newer Technologies
Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD
Desmond Tutu Health Foundation / University of Cape Town (UCT), South Africa
Roll Out of New Prevention Technologies
Sinead Delany-Moretlwe, MBBCh, PhD, DTM&H
Wits RHI, University of the Witwatersrand, South Africa
Oral Abstract Presentations II -
#5 - Moving from Rhetoric to Reality: Lessons Learned from Integrating Oral PrEP and Family Planning Services in Public Health Facilities in Nairobi, Kenya
Patriciah Jeckonia
Kenya
#6 - The Value of a Ring to Women in Kenya: A Willingness-to-Pay Study of the Dapivirine Vaginal Ring
Urbanus Kioko
Kenya
#8 - Incidence of Intimate Partner Violence and Associated Risk Factors Amongst Pregnant and Breastfeeding Women Living with HIV in Malawi
Tapiwa Tembo
Malawi
Mini-Oral Abstract Presentations I -
#9 - Depression and Anxiety in Couples Enrolled in a Trial of an Intervention for PMTCT and Family Health in Southwestern Kenya
Joash Adongo
Kenya
#10 - Collaboration with Traditional Birth Attendants in Akwa Ibom, Nigeria to Improve Access to HIV Testing Services Among Pregnant Women
Esther Nwanja
Nigeria
#12 - “You Tell Him that ‘Baby, I am Protecting Myself’”: Women’s Agency, Constraint, Stigma and the Potential for PrEP Use in Durban, South Africa
Nonhlonipho Bhengu
South Africa
#13 - Human Resources for Health: The Impact of Case Management Teams on Continuity of Treatment Among People Living with HIV (PLHIV) in Plateau State, Nigeria
Anita Ejideh
Nigeria
Session 7: COVID-19 Response and Realities in Low Socioeconomic Settings -
CSIGN - COVID-19 Surveillance Intensification in Ghana Network
William Ampofo, PhD
University Of Ghana / African Vaccine Manufacturing Initiative, Ghana
TRACE - Transmission of COVID-19 in Crowded Environments
Philip Smith, PhD
Desmond Tutu Health Foundation, South Africa
Session 9: Innovative HIV Testing Approaches -
Innovations in HIV Testing: Sexual Network Testing and Recency Testing
Andrew Auld, MD, PhD, MSc
The Global Fund, United States
Thursday, 12 May 2022
Session 10: HIV Care and Treatment -
Switching When Detectable with/out Resistance Testing
Nicholas Paton, MD, FRCP
National University of Singapore, Singapore
What Rx to Start, PH Approach vs Individualized Therapy
François Venter, MD, FCP, PhD
Ezintsha, University of the Witwatersrand, South Africa
Mini-Oral Abstract Presentations II -
#14 - Dolutegravir-Based Regimen Ensures High Virological Success Despite Prior Exposure to Efavirenz-Based First-Line ART: a Comparative Study in Cameroon
Ezechiel Ngoufack Jagni Semengue
Cameroon
#16 - Assessing the Impact of COVID-19 on HIV Virological Suppression in the Public Health Sector in South Africa
Somayya Sarang
South Africa
#17 - Do Integrase Strand Transfer Inhibitors Increase the Risk of Developing Diabetes Mellitus Type 2 Among Adult People Living with Human Immunodeficiency Virus as Compared to Other Antiretroviral Therapy? A Systematic Review and Meta-Analysis
Violet Dismas Kajogoo
Tanzania
#18 - High Transmitted Drug Resistance in Brazil: Unprecedented Levels of INSTI Resistance
Ricardo Diaz
Brazil
Mini-Oral Abstract Presentations III -
#19 - Does Differentiated Service Delivery for HIV Treatment Change Healthcare Providers Workload? Provider Views from Malawi, South Africa, and Zambia
Bevis Phiri
Zambia
#20 - Shifting from 3-Multimonth Prescribing (3MMP) to 6-Multimonth Prescribing (6MMP) Was Associated with Non-Inferior Outcomes for Adults on Antiretroviral Therapy in Rwanda
Brian Kwizera
Rwanda
#21 - Risk Factors for Frailty in a Geriatric Cohort on Long Term Antiretroviral Treatment in Uganda
Phoebe Mbabazi
Uganda
#22 - Accelerating HIV Epidemic Control in Benue State, Nigeria, 2019-2021: The APIN Program Experience
Mikhail Obaje
Nigeria
#23 - Community Antiretroviral Therapy Dispensation in Cameroon Associated with Superior Client Outcomes: A National Evaluation
Anastasie Mapassion Nga
Zambia
Session 11: Addressing COVID-19 Setbacks Among Women Professionals: Supporting Gender Sensitive Resilient Strategies -
Panel Discussion
Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD
Desmond Tutu Health Foundation / University of Cape Town (UCT), South Africa
Sabrina Bakeera-Kitaka, MD, PhD
Makerere University College of Health Sciences / Mulago National Referral Hospital, Uganda
Rhoda Wanyenze, MBChB, MPH, PhD
Makerere University College of Health Sciences, Uganda
Mini-Oral Abstract Presentations IV -
#24 - Directly Observed Therapy (DOT) for ART in Children to Attain Viral Suppression
Evelyn Matongo
Zambia
#25 - Leaving No One behind: The Impact of Kindergarten ART clinic on HIV Treatment Outcomes Among Children Enrolled in Kindergarten HIV Program at Lighthouse HIV Care Facilities
Ackim Sankhani
Malawi
#26 - Supporting Self-Management in Adolescents to Be Resilient and Thrive: an Intervention Development Study
Talitha Crowley
South Africa
#27 - Une Entrée Difficile Dans la Sexualité Pour les Adolescentes Séropositives au Sénégal, Entre Normes Sociales et VIH
Maimouna Diop
Senegal
#28 - Risks and Vulnerabilities Among Adolescent Girls and Young Women Accessing HIV Prevention Services at DREAMS Centers in Zambia
Namukale Nanyangwe
Zambia
Session 12: HIV in Children and Adolescents -
Dolutegravir Treatment Outcomes in Children Including Neonates
Victor Musiime, MBChB, MMed, PhD
Joint Clinical Research Centre/Makerere University, Uganda
Differentiated Care Services including Mental Health for Adolescents
Session 13: HIV and Comorbidities -
Progress in Treatment for Viral Hepatitis - What are the Implications for Treatment
Jürgen Rockstroh, MD
University of Bonn, Germany
HIV, Non-Communicable Disease, and Aging
Barbara Castelnuovo, MD, PhD
Infectious Diseases Institute (IDI), Makerere University, Uganda
Friday, 13 May 2022
Mini-Oral Abstract Presentations V -
#30 - Traditional Healer Delivered Support Improves Re-Linkage to Care and ART Adherence Among Defaulted PLWH in Rural Uganda
Matthew Ponticiello
United States
#31 - Behavioral Economic Incentives to Support HIV Treatment Adherence (BEST): One-Year Results of a Randomized Controlled Trial in Uganda
Peter Wabulaka
Uganda
#32 - Retention and Access to Viral Load of Key Populations Living with HIV (KPLHIV) : Cases of MSM Followed by the NGO SOUTOURA/EpiC in Mali
Almahdi Ag Alitini
Mali
Session 14: Structural Issues : Stigma and Discrimination -
Addressing Stigma in Health Facilities: Why It Matters and How It Can be Done
Laura Nyblade, PhD
RTI International, United States
Session 15: KP Programming -
Achieving HIV Epidemic Control Among KPs in Africa
Christopher Akolo, MD, MSc, FWACP
FHI 360, United States
Session 16: OVC Programming -
State of the Art Interventions in Improving Pediatric HIV Outcomes in OVC Programs
Grace Mayanja
FHI 360, Ethiopia
Session 17: HIV and HPV -
Integrating HPV Prevention in Adolescent HIV Care: Example of Friday Adolescent Clinic at Makerere University
Sabrina Bakeera-Kitaka, MD, PhD
Makerere University College of Health Sciences / Mulago National Referral Hospital, Uganda
Mini- Oral Abstract Presentations VI -
#34 - OK to Not Be OK in HIV Care: Lessons and Outcomes of Integration of Mental Health Screening, Referrals and Support in Routine HIV Care in Zimbabwe
Efison Dhodho
Zimbabwe
#35 - Factors Associated with Low Tuberculosis Case Notification and Treatment Success at Health Facilities in Zambia: A Cross Sectional Study
Tikulirekuti Banda
Zambia
#37 - Immunological Phases of Sepsis in a Ugandan Cohort with Significant HIV Co-Infection
Pritch Kagera Kabata
Uganda
#38 - High Prevalence of the Atypical Hepatitis B Virus Serology Profile: HBsAg Positive/Anti-HBc Negative in HBV and HIV Co-Infected People in Botswana
Bonolo Bonita Phinius
Botswana
General
Welcome

The annual INTEREST Conference is the premier scientific conference for HIV in Africa, and brought together scientists involved in HIV treatment, pathogenesis, and prevention research from around the world. The conference showcased cutting-edge knowledge in the diagnosis and treatment of HIV and the prevention of HIV-1 acquisition. Additionally, it continued to foster building a community of African physicians and scientists to facilitate the implementation of local solutions for the management of people living with HIV and for the prevention of HIV transmission.

INTEREST is co-organised by Amsterdam Institute for Global Health and Development (AIGHD) and Virology Education.

INTEREST 2022 took place in Kampala, Uganda, and the programme consisted of invited lectures, oral abstract presentations, a debate, skill-building sessions, panel discussions, and sponsored symposia.

Site Officiel de la Conférence

General Information 
Past Conferences
2007 – Kampala, Uganda
2008 – Dakar, Senegal
2009 – Lusaka, Zambia
2010 – Maputo, Mozambique
2011 – Dar Es Salaam, Tanzania
2012 – Mombasa, Kenya
2013 – Dakar, Senegal
2014 – Lusaka, Zambia
2015 – Harare, Zimbabwe
2016 – Yaounde, Cameroon
2017 – Lilongwe, Malawi
2018 – Kigali, Rwanda
2019 – Accra, Ghana
2020 – Windhoek, Namibia (Virtual Conference)
2021 – Virtual Conference
Practical Information 
Certificate of Attendance
A certificate of attendance will be sent to participants that have successfully completed the post-conference survey.
Language
The official language of the conference is English. French translation will be available.
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organising Secretariat of this conference, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this conference. The Scientific Secretariat of this conference, the Amsterdam Institute for Global Health and Development, cannot accept any liability for the logistical arrangements made for this conference or any risks associated with them.
Liability and Insurance
It is highly recommended that all participants carry proper individual travel and health insurance, as Virology Education, AIGHD and the INTEREST Conference cannot accept liability for accidents, illness, or injuries that may occur at or during the conference.
Photographs, Audio, and Video Recording
Recording of official meeting sessions either via camera, smartphone, or other audio/video recording devices is not permitted without the explicit consent of a speaker. Otherwise, only the official medical writers appointed by the INTEREST Conference Organisers may make recordings. Presentations will be posted on our website as soon as possible after the conference if the speaker has given the organisers permission to do so.
Support
Bronze Sponsor Level
Support Our Initiative

Financial backing helps us deliver an impactful meeting experience to the benefit of healthcare professionals and community representatives involved in HIV treatment, pathogenesis, and prevention research.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
 
To show your commitment to the cause and get in touch with us for a tailored support package, please contact either 

Karin Siebelt at Karin.Siebelt@vironet.com or call +31 30 230 7149, or
Marloes Nijboer at m.nijboer@aighd.org

Benefits of Support 
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

  • Symposium opportunities
  • Verbal acknowledgment during the program 
  • Discounted and complimentary registrations for your representatives
  • Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
  • Company acknowledgment on printed meeting materials including but not limited to banners and the program book
  • Digital and printed advertising opportunities 
  • Social media shout-outs
  • Logo on the conference bag 

*Subject to the support level

Media
Africans leading the research effort to control HIV and COVID-19 in Africa: The INTEREST Conference, Kampala, Uganda

Sub-Saharan Africa is home to 25.3 million (67%) of the global total of 37.7 million people living with HIV infection (UNAIDS 2021). To control the epidemic in Africa, it is essential that solutions for Africa be generated and implemented in Africa. The INTEREST Conference –now in its sixteenth year– is an excellent example of international cooperation intended to advance the fight against HIV in Africa by cultivating African scientists and stimulating innovative solutions on the continent.

Read more here

INTEREST 2022

Aidsmap reviewed the INTEREST 2022 Conference, highlighting sessions such as those on global health targets, vaginal rings & topical PrEP, HIV treatment in pregnancy, and more.

Read their article here

Language
Ratings previous edition
Content is relevant to my practice
4.8
(322)
Content was free from commercial bias
4.6
Overall event experience
4.8